To paraphrase Mark Twain, the death of the health insurance industry has been greatly exaggerated. Plans simply have to develop new business models.
The UC–Berkeley health care economist says the cost-control and performance-improvement methods we’ve been developing for years can work, but implementing them on a wide scale may come as a last resort
Provenge is just one example of an expensive biotechnology drug whose survival analyses leave much to be desired
Treating sleep apnea greatly reduces global costs, but compliance remains a concern
By segmenting services, employers limit their ability to leverage powerful data analyses that drive health improvement and cost reduction.
Legislation & Regulation
Health plan officials are not doing handstands over the federal government’s extension of a deadline to disclose benefits to members in a readable form
Insurers feel pressure to incorporate new agents into their drug benefit, but evidence of effectiveness is questionable
A summary of ECRI Institute’s Health Technology Forecast Report
The Formulary Files
Employers and the federal government like these programs, but some question their cost-effectiveness
There are many genetic mutations attributable to the condition, but Kalydeco can significantly help a specific subpopulation of patients
Thomas Morrow, MD
Managed Care Outlook